|1.||Dubois, Josée: 2 articles (05/2006 - 06/2003)|
|2.||Bruce, Colin E: 1 article (11/2009)|
|3.||Sampath, Jayanth Sundar: 1 article (11/2009)|
|4.||Bass, Alf: 1 article (11/2009)|
|5.||Unnikrishnan, Puthanveettil Nithin: 1 article (11/2009)|
|6.||Garg, Neeraj K: 1 article (11/2009)|
|7.||George, Harvey L: 1 article (11/2009)|
|8.||Desir, A: 1 article (09/2008)|
|9.||Duysinx, B: 1 article (09/2008)|
|10.||Dondelinger, R F: 1 article (09/2008)|
|1.||Lymphangioma (Cavernous Lymphangioma)
10/01/2000 - "In our experience, Ethibloc is particularly appropriate for the treatment of large lymphangiomas."
10/01/2000 - "It materialized as an Ethibloc exteriorization among 5 patients suffering from venous angiomas and 3 patients suffering from lymphangiomas and as an inflammatory lump for 2 venous angiomas carriers and for 4 lymphangiomas carriers. "
09/01/1997 - "The most frequent complication was leakage of Ethibloc without important sequelae in 10 of the 14 lymphangiomas. "
09/01/1997 - "Fourteen patients with macrocystic and mixed lymphangiomas were treated with use of Ethibloc as a sclerosing agent. "
01/01/1997 - "Between 1987 and 1993, 20 patients with a superficial macrocystic lymphangioma were treated by percutaneous injection of Ethibloc in order to reduce the volume of the CL, with a minimum follow-up of 1 year. "
01/01/1998 - "To achieve the burned out state of chronic pancreatitis, occlusion of the pancreatic duct was first attempted by our team with Ethibloc at ERCP. "
01/01/1989 - "Alcohol-induced chronic pancreatitis in rats after temporary occlusion of biliopancreatic ducts with Ethibloc."
01/01/1987 - "Altogether, Whipple's procedure plus intraoperative Ethibloc occlusion of the residual pancreatic duct system seems suitable for termination of the inflammatory process and thus preservation of residual endocrine pancreatic function in chronic pancreatitis."
12/17/1981 - "On the basis of a standardized, improved surgical technique, and the introduction of pancreatic ductal occlusion with Ethibloc to prevent recurrence, we have succeeded in achieving a considerable improvement in the early and late results of partial duodenopancreatectomy in the treatment of chronic pancreatitis; this improvement is reflected in a marked reduction in the surgical mortality rate from, formerly, 8.2 in 49 to 0.86% in 116 operations, together with, to date, very good late results, with freedom from symptoms in 90.2%, a recurrence rate of 1.1%, and a postoperative increase in weight of, on average, 7.8 kg in 85% of the cases so treated."
04/01/1990 - "We conclude that partial pancreaticoduodenectomy with occlusion of the pancreatic duct with Ethibloc is the procedure of choice in severe chronic pancreatitis mainly affecting the head of the gland."
06/01/1990 - "In a prospective follow-up study of 23 patients, Ethibloc duct occlusion was shown to be highly effective in inducing controlled atrophy of the gland and thereby terminating the inflammatory process. "
01/01/1983 - "Consequently, Ethibloc duct occlusion does not seem to be a superior alternative to other methods of producing exocrine atrophy in organs intended for transplantation."
11/01/1989 - "We conclude that Ethibloc occlusion is highly effective in inducing complete exocrine atrophy, thus abolishing the inflammatory process and preventing relapses of chronic pancreatitis and preserving the endocrine function from further impairment. "
04/01/1990 - "Partial pancreaticoduodenectomy with occlusion of the remaining tail of the pancreas with Ethibloc to induce rapid exocrine atrophy was introduced by us in January 1978 for the treatment of severe chronic pancreatitis affecting the head of the gland. "
11/01/1989 - "Partial duodenopancreatectomy and occlusion of the remaining ductal system by Ethibloc to induce rapid exocrine atrophy for treatment of severe chronic cephalic pancreatitis was introduced in our department in January of 1978. "
|4.||Aneurysmal Bone Cysts (Aneurysmal Bone Cyst)
11/01/2009 - "The aim of this study is to assess the long-term results of Ethibloc injection in aneurysmal bone cysts (ABC). "
10/01/2003 - "The purpose of this study is to report the results of direct Ethibloc injection in primary aneurysmal bone cyst (ABC) in children. "
11/01/2009 - "Long-term follow-up of Ethibloc injection in aneurysmal bone cysts."
05/01/2006 - "Nevertheless, the complications encountered in some series after percutaneous embolization of aneurysmal bone cyst with Ethibloc should encourage the use of Ethibloc injection not as an initial treatment but as a reliable alternative to surgery."
09/01/2005 - "Direct ethibloc injection of aneurysmal bone cysts."
11/01/2006 - "Injection of sclerosing agent (Ethibloc) was indicated in 4 cases because of the volume of the tumor. "
01/01/1989 - "Contrary to other angioocclusive treatment modalities, the concept of capillary occlusion with Ethibloc seems to achieve total tumor destruction."
10/01/1984 - "[Palliative embolization of kidney tumors using iodol-marked Ethibloc]."
09/01/1980 - "The second embolization with Ethibloc provoked a regression of the tumor."
01/01/1988 - "Two patients with abdominal hemorrhage from a hepatic tumor underwent transcatheter embolization using Ethibloc. "
|1.||Ethiodized Oil (Ethiodol)
|2.||Anti-Bacterial Agents (Antibiotics)
|3.||Ethanol (Ethyl Alcohol)
|9.||Fibrin Tissue Adhesive (Fibrin Sealant)
|10.||Biological Markers (Surrogate Marker)